Tinzaparin sodium
| Clinical data | |
|---|---|
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number |
|
| ECHA InfoCard | 100.110.590 |
Tinzaparin is an antithrombotic in the heparin group. It is a low-molecular-weight heparin with 4500 Dalton in average. It has been approved by the FDA for once-daily treatment of deep vein thrombosis and pulmonary embolism.[2]
References
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
- ^ Hull, New England Journal of Medicine, 1992
External links
- tinzaparin at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
- Sprigg N, Gray LJ, Bath PM; et al. (2007). "Early recovery and functional outcome are related with causal stroke subtype: data from the tinzaparin in acute ischemic stroke trial". Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association. 16 (4): 180–4. doi:10.1016/j.jstrokecerebrovasdis.2007.02.003. PMID 17689415.
{{cite journal}}: Explicit use of et al. in:|author=(help)CS1 maint: multiple names: authors list (link)
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |